Yüklüyor......
Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study
Rurioctocog alfa pegol prophylaxis targeting factor VIII (FVIII) troughs ≥1% has shown to be efficacious with an acceptable safety profile in people with hemophilia A (PwHA). The PROPEL trial compared safety and efficacy of 2 target FVIII troughs in PwHA aged 12 to 65 years, with severe disease, ann...
Kaydedildi:
| Yayımlandı: | Blood |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8039905/ https://ncbi.nlm.nih.gov/pubmed/33150384 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005673 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|